Cannara Biotech Inc. announced its fiscal first quarter 2025 financial and operating results for the three-month period ended November 30, 2024. The Q1 2025 results delivered the strongest quarter in company history, producing records for market share, revenue, adjusted EBITDA, operating cash flow, and free cash flow showcasing a successful execution of the company’s long-term business strategy and industry leadership.

Cannara Biotech Inc., a client of our Bristol Investor Relations company, is a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft.

Read the full press release here: Cannara Biotech Reports Record Q1 2025 Revenue and National Market Share, Sets Stage for Continued Momentum in 2025